Clinical Trials Browser

Phase 1/2 × pevonedistat × Tumor-Agnostic × Clear all

NCT04800627 2022-12-27

Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor

Phase 1/2 Terminated

2 enrolled 4 charts

Neoplasm Metastasis